|
|||||
|
|
| 替比夫定治疗慢性乙型肝炎的研究进展 | |
| 引用本文： | 王海燕,王煜,彭晓明,刘娅. 替比夫定治疗慢性乙型肝炎的研究进展[J]. 临床肝胆病杂志, 2011, 27(12): 1320-1322,1326 |
| 作者姓名： | 王海燕 王煜 彭晓明 刘娅 |
| 作者单位： | 1. 宁夏医科大学,银川,750004 2. 宁夏医科大学总医院感染疾病科,银川,750004 |
| 基金项目： | 宁夏自然科学基金(NZ10118) |
| 摘 要： | 替比夫定是一种新型的抗HBV作用的核苷类似物，其HBeAg血清学转换率高、起效早，耐药发生率低。了解替比夫定的药理作用，选择合适的病例进行治疗，在治疗过程中及时监测，根据第24周时患者的HBVDNA水平来指导后期的治疗，有助于达到长期抑制HBV的目的。 |
| 关 键 词： | 肝炎 乙型 慢性 肝炎病毒 替比夫定 |
Recent advancement of telbivudine in the treatment of chronic hepatitis B |
|
| WANG Hai-yan,WANG Yu,PENG Xiao-ming,et al.. Recent advancement of telbivudine in the treatment of chronic hepatitis B[J]. Chinese Journal of Clinical Hepatology, 2011, 27(12): 1320-1322,1326 | |
| Authors: | WANG Hai-yan WANG Yu PENG Xiao-ming et al. |
| Affiliation: | WANG Hai-yan,WANG Yu,PENG Xiao-ming,et al.(Ningxia Medical University,Yinchuan 750004,China) |
| Abstract: | Telbivudine is a novel nucleoside analogue against hepatitis B virus with fast HBeAg seroconversion rate,early viral response and low drug tolerance rate.It is helpful in achieving the long term suppression of HBV by understanding the pharmacokinetics of Telbivudine,selecting the appropriate patients for treatment,timely monitoring the patients during treatment and guiding post-treatment by the patient's first 24 weeks HBV-DNA levels. |
| Keywords: | hepatitis B chronic hepatitis B virus telbivudine |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ | |